reports
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 6, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from April 29, 2024 to May 3, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement 602,818 1,222,541,085.50April 29, 202...
- Carole Braudeau
- Carole Braudeau
- Jerôme Bodin
ODDO BHF Small & MIDCAP MORNING NEWS - 03/05/2024
Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...
- Jerôme Bodin
ODDO BHF Small & MIDCAP MORNING NEWS - 05/03/2024
Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...
- Damien Choplain
- Martial Descoutures
Galapagos : Largely unsurprising numbers
>Solid cash position - Galapagos reported its Q1 earnings after the close in the US. Group revenues came in at € 100m vs € 83m expected. The bulk stemmed from its agreement with Gilead for € 62m while net product sales amounted to € 37m. At the operating level, costs were broadly under control, with total expenditure of around € 129m vs € 110m although we note an increase of close to 36% in R&D expense due to the development of the clinical portfolio. In contrast...
- Dominic Rose
- Naresh Chouhan
Sanofi - The Path to €120 (BUY, TP EUR120 [110], 7pgs)
This new analysis shows how Sanofi shares get to €120 (+c.30%) by end 2025. We have conducted a foundational analysis that investors can refer to over the next 18mths as Sanofi releases at least 15 P2 & P3 pipeline readouts. We show the upside potential from every single readout and show that just 4 drugs could add €18/share upon successful readouts. In addition to multiple readouts, the likely Consumer Health spin in Q4, the tolebrutinib overhang being resolved one way or another and a strong C...
- Damien Choplain
- Martial Descoutures
Galapagos : Une publication sans grande surprise
>Une trésorerie solide - Galapagos publiait après la fermeture du marché US ses résultats du T1. Les revenus du groupe ressortent ainsi à 100 M€ vs 83 M€ att. L’essentiel des revenus vient de son accord avec Gilead pour 62 M€ alors que les ventes des produits nets ressortent à 37 M€. Au niveau opérationnel, les coûts sont globalement bien maitrisés ce qui conduit à avoir des dépenses totales de l’ordre de 129 M€ vs 110 M€ même si nous observons une hausse de près...
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Sharad Kumar S.P
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Galapagos FIRST LOOK: uneventful 1Q24 results, FY24 cash burn guidance...
Galapagos reported uneventful 1Q24 results and confirmed its FY24 cash burn guidance of € 280-320m (FY23: € 414.8m), thanks to the savings from the transfer of Jyseleca to Alfasigma. While the company did not provide an update on timelines for its pipeline, we think data updates from the phase 1/2 CAR-T trials in r/r NHL and r/r CLL could come at upcoming scientific conferences (e.g. ASH in December 2024). Beyond that, BD remains on the table and we'd like to see an acceleration on that front wi...
- David Seynnaeve
- PhD
Galapagos - Q1 24 results
GLPG published its Q1 results, reporting Group net revenues of EUR 100m, in line with CSS. Net profit was significantly up (but below CSS), notably boosted by preliminary calculation of the gain on the sale of Jyseleca.FY24 reduced cash burn guidance reiterated. Nothing new on the CAR-T front. Yet, it is good to see that the company still plans to submit IND applications for its CAR-Ts still in 2024. Remember that GLPG has been running CAR-T trials in Europe only so far.Overall, no material surp...
- Rune Majlund Dahl
Genmab (Buy, TP: DKK2630.00) - Epinkly off to a good start in 2024
Q1 sales beat our forecast and consensus due to higher product-related royalties and solid Epkinly sales, while the operating profit margin was softer than expected owing to higher opex. Genmab reiterated the 2024 guidance for sales of DKK18.7bn–20.5bn, opex of DKK12.4bn–13.4bn, and operating profit of DKK4.6bn–7.1bn. We expect a strong pipeline of news flow in 2024. We reiterate our BUY and DKK2,630 target price.
Galapagos reports first quarter 2024 financial results
Galapagos reports first quarter 2024 financial results Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunologyExecuted agreements with BridGene Biosciences and Thermo Fisher Scientific, and investment in Frontier MedicinesTransferred Jyseleca® business to Alfasigma S.p.A., freeing up resources to invest in growth areasGroup net revenues in the first quarter of €100 millionCash and current financial investments of €3.6 billion on 31 March 2024Reconfirmed 2024 cash burni guidance o...
Galapagos rapporteert financiële resultaten voor het eerste kwartaal 2...
Galapagos rapporteert financiële resultaten voor het eerste kwartaal 2024 Vooruitgang met potentiële best-in-class R&D pijplijn van celtherapie en kleine moleculen, met vier klinische assets en >15 onderzoeksprogramma's in oncologie en immunologie Overeenkomsten afgesloten met BridGene Biosciences en Thermo Fisher Scientific, en investering in Frontier MedicinesJyseleca® business overgedragen aan Alfasigma S.p.A., waardoor middelen vrijkomen om te investeren in groeigebiedenNetto groepsomzet in het eerste kwartaal van €100 miljoenGeldmiddelen en kortlopende financiële investeringen van €...
Genmab Announces Financial Results for the First Quarter of 2024
Genmab Announces Financial Results for the First Quarter of 2024 May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY® (epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, with a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2024An additional Phase 3 clinical trial was initiated...
Press Release: Beyfortus real-world evidence published in The Lancet s...
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the o...
Communiqué de presse : Des données de vie réelle concernant Beyfortus ...
Communiqué de presse : Des données de vie réelle concernant Beyfortus publiées dans The Lancet montrent une réduction de 82 % des hospitalisations de nourrissons dues au VRS Des données de vie réelle concernant Beyfortus publiées dans The Lancet montrent une réduction de 82 % des hospitalisations de nourrissons dues au VRS De nouvelles données de vie réelle montrent que Beyfortus (nirsevimab) a permis de réduire sensiblement les infections des voies respiratoires inférieures dues au VRS chez les nourrissons, de même que les hospitalisations, au cours de la saison virale 2023-2024, compa...
Sanofi: 1 director
A director at Sanofi bought 1,000 shares at 91.380EUR and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...
Galapagos’ shareholders adopt all resolutions proposed by the Board of...
Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024 Mechelen, Belgium; 30 April 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the company’s Annual and Extraordinary Shareholders’ Meetings (AGM and EGM) held on 30 April 2024 were approved. The AGM approved, amongst other items: The Remuneration Report and revised Remuneration PolicyThe remuneration of the members of the Board of DirectorsThe reappointment of Dr. Elisabeth Svanberg as Independent...
Galapagos’ aandeelhouders keuren alle door de Raad van Bestuur voorges...
Galapagos’ aandeelhouders keuren alle door de Raad van Bestuur voorgestelde besluiten goed op de jaarlijkse Gewone en Buitengewone Algemene Aandeelhoudersvergaderingen 2024 Mechelen, België; 30 april 2024; 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) maakt vandaag bekend dat alle voorstellen tot besluit op de jaarlijkse Gewone en Buitengewone Algemene Aandeelhoudersvergaderingen van 30 april 2024 zijn goedgekeurd. De jaarlijkse Gewone Algemene Aandeelhoudersvergadering keurde onder meer goed: Het Remuneratieverslag en gewijzigde RemuneratiebeleidDe bezoldiging van de BestuurdersDe he...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.